Not Cleared Direct

DEN200043 - FilmArray Global Fever Panel (FDA 510(k) Clearance)

Nov 2020
Decision
147d
Days
Class 2
Risk

DEN200043 is an FDA 510(k) submission for the FilmArray Global Fever Panel. This device is classified as a Device To Detect And Identify Selected Microbial Agents That Cause Acute Febrile Illness (Class II - Special Controls, product code QMV).

Submitted by Biofire Defense, LLC (Salt Lake City, US). The FDA issued a Not Cleared (DENG) decision on November 20, 2020.

This device falls under the Microbiology FDA review panel. Regulated under 21 CFR 866.3966. A Device To Detect And Identify Selected Microbial Agents That Cause Acute Febrile Illness Is Identified As A In Vitro Device Intended For The Detection And Identification Of Microbial Agents In Human Clinical Specimens From Patients With Signs And Symptoms Of Acute Febrile Illness Who Are At Risk For Exposure Or Who May Have Been Exposed To These Agents. It Is Intended To Aid In The Diagnosis Of Acute Febrile Illness In Conjunction With Other Clinical, Epidemiologic, And Laboratory Data, Including Patient Travel, Pathogen Endemicity, Or Other Risk Factors..

Submission Details

510(k) Number DEN200043 FDA.gov
FDA Decision Not Cleared Not Substantially Equivalent (DENG)
Date Received June 26, 2020
Decision Date November 20, 2020
Days to Decision 147 days
Submission Type Direct
Review Panel Microbiology (MI)
Summary -

Device Classification

Product Code QMV - Device To Detect And Identify Selected Microbial Agents That Cause Acute Febrile Illness
Device Class Class II - Special Controls
CFR Regulation 21 CFR 866.3966
Definition A Device To Detect And Identify Selected Microbial Agents That Cause Acute Febrile Illness Is Identified As A In Vitro Device Intended For The Detection And Identification Of Microbial Agents In Human Clinical Specimens From Patients With Signs And Symptoms Of Acute Febrile Illness Who Are At Risk For Exposure Or Who May Have Been Exposed To These Agents. It Is Intended To Aid In The Diagnosis Of Acute Febrile Illness In Conjunction With Other Clinical, Epidemiologic, And Laboratory Data, Including Patient Travel, Pathogen Endemicity, Or Other Risk Factors.